Caris Life Sciences announced that its Board of Directors authorized a program to repurchase up to $100 million of its outstanding common stock. The precision medicine and AI TechBio company plans to execute repurchases through open market purchases, private negotiations, or Rule 10b5-1 trading plans, adhering to federal securities laws including Rule 10b-18. Management will determine the timing and scale based on market conditions, stock price, and financial health, using existing cash reserves. The program has no expiration date and does not obligate the company to acquire a specific number of shares, and the Board may modify or suspend it at any time.
Caris Life Sciences, Inc. Common StockCompany authorizes $100M share buyback, signaling confidence and returning capital to shareholders.